[go: up one dir, main page]

WO1999037810A1 - A method, reagent solution and kits for dna sequencing - Google Patents

A method, reagent solution and kits for dna sequencing Download PDF

Info

Publication number
WO1999037810A1
WO1999037810A1 PCT/US1999/001084 US9901084W WO9937810A1 WO 1999037810 A1 WO1999037810 A1 WO 1999037810A1 US 9901084 W US9901084 W US 9901084W WO 9937810 A1 WO9937810 A1 WO 9937810A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymerase
solution
substituent
labeled
labeled dideoxynucleotides
Prior art date
Application number
PCT/US1999/001084
Other languages
French (fr)
Inventor
Carl W. Fuller
Joseph A. Mamone
Bernard F. Mcardle
Kristine M. Hujer
Original Assignee
Amersham Pharmacia Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amersham Pharmacia Biotech, Inc. filed Critical Amersham Pharmacia Biotech, Inc.
Priority to EP99904129A priority Critical patent/EP1071812A4/en
Priority to JP2000528716A priority patent/JP2002510466A/en
Publication of WO1999037810A1 publication Critical patent/WO1999037810A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing

Definitions

  • the present invention relates to buffer solutions for use in DNA sequencing and to the use of such solutions.
  • DNA sequencing by the Sanger, or chain termination method has been in common use for some years.
  • the sample to be sequenced may be split into four portions, and each portion may be hybridized to a suitable primer and the primer extended using a DNA polymerase and deoxynucleotides.
  • the incorporation of different dideoxynucleotides in the reaction mixture terminates the chain extension reaction at consecutive positions so that a collection of DNA fragments is obtained each differing by one nucleotide.
  • T7 DNA polymerase or E.coli DNA polymerase is used in such a procedure.
  • thermostable DNA polymerases which incorporate dideoxynucleotides (ddNTPs) as efficiently as deoxynucleotides, thereby enabling the concentration of the former to be reduced, greatly facilitating the sequencing process (see European Patent No. 655506 Bl).
  • ddNTPs dideoxynucleotides
  • Thermostable Pol I family DNA polymerases in which a phenylalanine in the nucleotide binding domain has been replaced by tyrosine and the exonuclease activity reduced or deleted are particularly advantageous.
  • Such polymerases have been marketed by the ABD division of the Perkin-Elmer Corporation under the trademark AMPLITAQ FS and by Amersham Life Science under the trademark THERMO_SEQUENASE - these are both mutated Thermus aquaticus enzymes.
  • results obtained from sequencing reactions when using substituent-labeled, e.g., dye- labeled, ddNTPs and thermostable Pol I family DNA polymerases can be improved by adding a particular concentration of manganese and tartaric acid or an equivalent metal ion buffer.
  • the improved results are observed as less variation in band intensity (peak height) than is usually obtained when using the same dye-labeled ddNTPs without manganese ions.
  • the present invention provides a solution that contains manganese ion at a concentration of between 0.5mM to 3.0mM and a metal ion buffer at a concentration of 5mM to 50mM.
  • concentration of manganese is preferably between 0.5mM and l.OmM, or between 0.5mM and 2.0mM, or between 0.5mM and 2.5mM, with about 0.8mM being most preferable in the absence of a metal ion buffer, and about 1.5 mM being most preferable in the presence of a metal ion buffer.
  • the manganese concentration in the solution is less than 3.0mM in a polymerization reaction mixture.
  • concentration of the metal ion buffer is preferably between 5mM and 50mM.
  • the solution will preferably be pH buffered to a pH between 6 and 8.5, for example about pH
  • pH buffer refers to a material which regulates the concentration of hydronium ion, H 3 O + (or dissociated protons), in solution.
  • a pH buffer regulates the concentration of hydronium ion or dissociated protons in solution by resisting changes in the concentration of the ion in response to dilutions or to additions or subtractions of acids or bases from the solution. Buffers for regulating pH (as distinct from metal ion buffers) which lack primary amino groups, such as tertiary amine buffers are preferred pH buffering agents.
  • the buffer compound is preferably one which does not interfere with with a sequencing reaction in which the solution is to be used.
  • the solution is an aqueous solution.
  • substituted-labeled dd ⁇ TP or "substituent-labeled dideoxynucleotide triphosphate” or "substituent-labeled dideoxynucleotide” is meant a 2'-deoxyribonucleotide analog which has a covalently attached detectable group and which lacks a functional 3'-hydroxyl group, so that it terminates chain elongation catalyzed by D ⁇ A polymerase.
  • the substituent detectable group provides an additional atom or group to the dd ⁇ TP structure, and therefore does not consist of the replacement of an atom in the dd ⁇ TP structure with a radioactive isotope, e.g., 32 P.
  • the substituent label is a dye label, more preferably a fluroescent dye label.
  • Dye labels are chemical groups which are detectable spectrophotometrically, preferably be the emission or reflection of light of characteristic wavelengths. Such nucleotides and appropriate dye labels are well known in the art, for example, as described in Lee at al., 1992, Nucl. Acids Res.
  • metal ion buffer is meant a material which regulates the concentration of free metal ion, such as Mn 2+ , in solution.
  • a buffer regulates the concentration of a species (e.g., a metal ion) in solution by resisting changes in the concentration of the free ion in response to dilutions or to additions or subtractions of that ion from the solution.
  • a buffer can, for example, be a dicarboxylic acid, e.g., an alkyldicarboxylic acid such as tartaric acid, where alkyl is a straight or branched chain of 1,2,3,4,5 . 6,7, or 8 carbon atoms.
  • dicarboxylic acids include oxalic acid, malonic acid, succinic acid, maleic acid, glutaric acid, adipic acid, fumaric acid, glutamic acid, aspartic acid, and phthalic acid.
  • metal ion buffers include, for example, citric acid, EDTA (ethylenediaminetetraacetic acid), nitrilotriacetic acid, diethenetriaminepentaacetic acid, N-hydroxyethyliminodiacetic acid, 2-( ⁇ - morpholino)ethanesulfonic acid, dithiothreitol, and NN-bishydroxyethylglycine).
  • a metal ion buffer may be used in the presence of a pH buffer (i.e., a compound which regulates the concentration of free H + in solution).
  • the manganese ion will normally come from a salt, for example manganese sulphate (MnSO 4 ), manganese chloride (MnCl 2 ), or manganese acetate.
  • dicarboxylic acid is meant any lower alkyl, hydroxyalkyl, or aminoalkyl compound containing two carboxylic acid groups, such as oxalic acid, malonic acid, succinic acid, maleic acid, tartaric acid, glutaric acid, adipic acid, fumaric acid, phthalic acid, glutamic acid, or aspartic acid.
  • the invention provides a kit for D ⁇ A sequencing which includes reagents necessary for D ⁇ A sequencing including manganese and a metal ion buffer, preferably at the concentrations specified above or in concentrations readily diluted to those specified above.
  • the kit includes a Pol I family D ⁇ A polymerase that contains a tyrosine in the nucleotide binding domain of the polymerase at a position analogous to that occupied by phenylalanine in unmutated D ⁇ A polymerase (e.g. at position 667 in Thermus aquaticus 5 DNA polymerase I).
  • the DNA polymerase is a thermostable polymerase, preferably a Thermus aquaticus polymerase that has been mutated to replace the phenylalanine at position 667 with tyrosine and in which the exonuclease activity has been substantially removed, e.g. less than 1% of exonuclease activity remains.
  • the kit also includes dye-labeled ddNTPs, e.g. ddATP, ddCTP, ddGTP and ddTTPs.
  • the kit for DNA sequencing will preferably contain, as a first component, a metal ion buffer together with a buffering agent for regulating the pH to between pH 6 and pH 9, preferably about pH 8, deoxynucleotides and dye-labeled ddNTPs, and, as a second component, manganese ion together with a buffering agent for regulating the pH to between pH 3 to pH 7, preferably about pH 6, for example 2-(N-morpholino)ethanesulfonic acid.
  • a DNA polymerase may also be included in the kit, preferably a DNA Pol I polymerase and most preferably a thermostable DNA polymerase, that contains a tyrosine in the dideoxy binding domain at a position analogous to that occupied by phenylalanine in unmutated polymerase.
  • the kit may also contain a pyrophosphatase, for example, an inorganic pyrophosphatase such as that from Thermoplasma acidophilwn.
  • the polymerase and pyrophosphatase will conveniently be included in the first component of the kit.
  • the kit may also contain sources of other metal ions, for example magnesium and conveniently salts of such metal ions. These additional optional metal ions will conveniently be in the second component of the kit.
  • the concentration of the manganese ions and metal ion buffer will be such that they can be mixed directly to give the concentrations required for the sequencing reaction or they can be diluted readily to give the required concentrations. While the second component containing the manganese ions is buffered to about pH 6, the mixture resulting from adding the two components together will have a pH of about 8, e.g. pH 7 to pH 9.
  • the present invention provides a method for sequencing DNA which comprises performing a DNA sequencing reaction in the presence of dye-labeled ddNTPs and manganese, at a concentration of between 0.5mM and 3mM, and preferably also in the 6 presence of a metal ion buffer, for example tartaric acid, at a concentration of between 5mM and 50mM, in the reaction mixture.
  • a metal ion buffer for example tartaric acid
  • the present invention provides a solution containing a metal ion buffer together with a buffering agent for regulating the pH to about pH 8, deoxynucleotides, and dye-labeled ddNTPs.
  • a buffering agent for regulating the pH to about pH 8, deoxynucleotides, and dye-labeled ddNTPs.
  • the solution also contains a thermostable Pol I family DNA polymerase, more preferably a polymerase which has a tyrosine substituted for a phenylalanine in the nucleotide binding site.
  • Figure 1 shows DNA sequencing results from an automated fluorescent DNA sequencing apparatus (ABI model 373 instrument) for an exemplary sequencing in which the polymerization step was carried out in the presence of manganese and a metal ion buffer.
  • Figure 2 shows DNA sequencing results corresponding to the results shown in Fig. 1, except that manganese was not included in the reaction mix.
  • Figure 3 shows the structure of the four dye labeled dideoxynucleotides utilized in the examples below. Each of the structures is identified with a Roman numeral, which is referenced in the solution preparation in Example 1.
  • the volume was made up to 10 ml with deionized H 2 O.
  • 4 ⁇ l reagent mix A, 4 ⁇ l reagent mix B, 200 ng M13mp 18 DNA, 5 pmole of primer (M13 - 40 Forward 5'-GTTTTCCCAGTCACGAC), and deionized water to a total volume of 20 ⁇ l were mixed together and subjected to 25 cycles of 96°C 30 seconds, 50°C 15 seconds, and 60°C 4 minutes in a thermal cycler. After cycling, 4 ⁇ l of a solution which contained 1.5 M sodium acetate, 250 mM EDTA was added. The solution was mixed and 4 volumes (lOO ⁇ l) of ethanol added. The DNA was precipitated by incubation on ice for 15-20 minutes followed by centrifugation.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Solutions are disclosed which improve the efficiency of DNA sequencing reactions using substituent-labeled, e.g., dye-labeled ddNTPs, and thermostable DNA polymerase. The components of the solution include an effective concentration of manganese ion and a metal ion buffer compound. The use of such solutions is also described.

Description

1
DESCRIPTION
A METHOD, REAGENT SOLUTION AND KITS FOR DNA SEQUENCING
Field of the Invention
The present invention relates to buffer solutions for use in DNA sequencing and to the use of such solutions.
Background of the Invention The following is a discussion of the relevant art, none of which is admitted to be prior art to the appended claims.
DNA sequencing by the Sanger, or chain termination method, has been in common use for some years. The sample to be sequenced may be split into four portions, and each portion may be hybridized to a suitable primer and the primer extended using a DNA polymerase and deoxynucleotides. The incorporation of different dideoxynucleotides in the reaction mixture terminates the chain extension reaction at consecutive positions so that a collection of DNA fragments is obtained each differing by one nucleotide. Frequently T7 DNA polymerase or E.coli DNA polymerase is used in such a procedure. Tabor and Richardson {Proc. Natl. Acad. Sci. USA 86:4076-4080 (1989)) indicate that the substitution of manganese ions for magnesium ions, which act as a cofactor in DNA sequencing using T7 DNA polymerase or E. coli DNA polymerase, reduces the discrimination of these polymerases for dideoxynucleotides (ddNTPs) by 4-100 fold and in J. Biol. Chem. 265:8322-8328 (1990) describe the use of manganese ions and pyrophosphatase to generate dideoxy-terminated fragments of uniform intensity using T7 DNA polymerase. However, these enzymes do not operate optimally when dye-labeled ddNTPs are used in the sequencing reaction.
A major improvement in the use of Sanger sequencing has been the discovery of a class of thermostable DNA polymerases which incorporate dideoxynucleotides (ddNTPs) as efficiently as deoxynucleotides, thereby enabling the concentration of the former to be reduced, greatly facilitating the sequencing process (see European Patent No. 655506 Bl). 2 Thermostable Pol I family DNA polymerases in which a phenylalanine in the nucleotide binding domain has been replaced by tyrosine and the exonuclease activity reduced or deleted are particularly advantageous. Such polymerases have been marketed by the ABD division of the Perkin-Elmer Corporation under the trademark AMPLITAQ FS and by Amersham Life Science under the trademark THERMO_SEQUENASE - these are both mutated Thermus aquaticus enzymes.
In using Pol I family DNA polymerases containing the tyrosine for phenylalanine substitution and 32P labeled dideoxynucleotides, Tabor & Richardson (Proc. Natl. Acad. Sci. USA 92:6339-6343 (1995)) reported that the substitution of manganese for magnesium in the reaction mixture had no significant effect on the use of ddNTPs by E. coli DNA polymerase I F762Y and Tag DNA polymerase F667Y.
Summary of the Invention The results obtained from sequencing reactions when using substituent-labeled, e.g., dye- labeled, ddNTPs and thermostable Pol I family DNA polymerases can be improved by adding a particular concentration of manganese and tartaric acid or an equivalent metal ion buffer. The improved results are observed as less variation in band intensity (peak height) than is usually obtained when using the same dye-labeled ddNTPs without manganese ions.
Accordingly, the present invention provides a solution that contains manganese ion at a concentration of between 0.5mM to 3.0mM and a metal ion buffer at a concentration of 5mM to 50mM. The concentration of manganese is preferably between 0.5mM and l.OmM, or between 0.5mM and 2.0mM, or between 0.5mM and 2.5mM, with about 0.8mM being most preferable in the absence of a metal ion buffer, and about 1.5 mM being most preferable in the presence of a metal ion buffer. Preferably, the manganese concentration in the solution is less than 3.0mM in a polymerization reaction mixture. The concentration of the metal ion buffer is preferably between 5mM and 50mM.
The solution will preferably be pH buffered to a pH between 6 and 8.5, for example about pH
8. The pH is chosen to be compatible with a sequencing reaction when the solution is 3 combined with al other needed reagents, if any. A "pH buffer" refers to a material which regulates the concentration of hydronium ion, H3O+ (or dissociated protons), in solution. A pH buffer regulates the concentration of hydronium ion or dissociated protons in solution by resisting changes in the concentration of the ion in response to dilutions or to additions or subtractions of acids or bases from the solution. Buffers for regulating pH (as distinct from metal ion buffers) which lack primary amino groups, such as tertiary amine buffers are preferred pH buffering agents. Examples include, HEPPS [N-(2-hydroxyethyl)piperazine-N- (3-propanesulfonic acid)], MES [(2-(N-mo holino)ethanesulfonic acid)], PIPES [piperazine- NN-bis(2-ethanesulfonic acid))], MOPS [(3-(N-morpholino)propanesulfonic acid)], HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid)]). The buffer compound is preferably one which does not interfere with with a sequencing reaction in which the solution is to be used. Preferably, the solution is an aqueous solution.
By "substituent-labeled ddΝTP" or "substituent-labeled dideoxynucleotide triphosphate" or "substituent-labeled dideoxynucleotide" is meant a 2'-deoxyribonucleotide analog which has a covalently attached detectable group and which lacks a functional 3'-hydroxyl group, so that it terminates chain elongation catalyzed by DΝA polymerase. While a radioactive isotope may be present in a substituent-labeled ddΝTP as used in this invention, the substituent detectable group provides an additional atom or group to the ddΝTP structure, and therefore does not consist of the replacement of an atom in the ddΝTP structure with a radioactive isotope, e.g., 32P. Preferably the substituent label is a dye label, more preferably a fluroescent dye label. Dye labels are chemical groups which are detectable spectrophotometrically, preferably be the emission or reflection of light of characteristic wavelengths. Such nucleotides and appropriate dye labels are well known in the art, for example, as described in Lee at al., 1992, Nucl. Acids Res. 20:2471 -2483 (describing the effects of dyes and dΝTPs on the incorporation of dye-terminators in DΝA sequencing); Prober et al., U.S. Patent 5,332,666, issued July 26, 1994 (and related patents 5,242,796 and 5,306,618 (describing method and reagents for DΝA sequencing using reporter-labeled (e.g., dye-labeled) chain terminators); and Bergot et al., Internal Patent Application PCT/US90/05565, WO 91/05060 (describing a set of rhodamine dyes and their use in DΝA sequencing using Taq DΝA
Polymerase with magnesium or manganese, or modified T7 DΝA Polymerase with 4 manganese). In the following description, the term "dye-labeled" is generally used, however, it should be recognized that the buffer solution of the present invention can also provide enhancement with ddNTPs labeled with other detectable substituents. Therefore, the various aspects of this invention include the use of additional substituent-labeled ddNTPs.
By "metal ion buffer" is meant a material which regulates the concentration of free metal ion, such as Mn2+, in solution. A buffer regulates the concentration of a species (e.g., a metal ion) in solution by resisting changes in the concentration of the free ion in response to dilutions or to additions or subtractions of that ion from the solution. Such a buffer can, for example, be a dicarboxylic acid, e.g., an alkyldicarboxylic acid such as tartaric acid, where alkyl is a straight or branched chain of 1,2,3,4,5.6,7, or 8 carbon atoms. Other examples of dicarboxylic acids include oxalic acid, malonic acid, succinic acid, maleic acid, glutaric acid, adipic acid, fumaric acid, glutamic acid, aspartic acid, and phthalic acid. Other metal ion buffers include, for example, citric acid, EDTA (ethylenediaminetetraacetic acid), nitrilotriacetic acid, diethenetriaminepentaacetic acid, N-hydroxyethyliminodiacetic acid, 2-(Ν- morpholino)ethanesulfonic acid, dithiothreitol, and NN-bishydroxyethylglycine). A metal ion buffer may be used in the presence of a pH buffer (i.e., a compound which regulates the concentration of free H+ in solution). The manganese ion will normally come from a salt, for example manganese sulphate (MnSO4), manganese chloride (MnCl2), or manganese acetate.
By "dicarboxylic acid" is meant any lower alkyl, hydroxyalkyl, or aminoalkyl compound containing two carboxylic acid groups, such as oxalic acid, malonic acid, succinic acid, maleic acid, tartaric acid, glutaric acid, adipic acid, fumaric acid, phthalic acid, glutamic acid, or aspartic acid.
In a related aspect, the invention provides a kit for DΝA sequencing which includes reagents necessary for DΝA sequencing including manganese and a metal ion buffer, preferably at the concentrations specified above or in concentrations readily diluted to those specified above. Suitably, the kit includes a Pol I family DΝA polymerase that contains a tyrosine in the nucleotide binding domain of the polymerase at a position analogous to that occupied by phenylalanine in unmutated DΝA polymerase (e.g. at position 667 in Thermus aquaticus 5 DNA polymerase I). Preferably the DNA polymerase is a thermostable polymerase, preferably a Thermus aquaticus polymerase that has been mutated to replace the phenylalanine at position 667 with tyrosine and in which the exonuclease activity has been substantially removed, e.g. less than 1% of exonuclease activity remains. Suitably, the kit also includes dye-labeled ddNTPs, e.g. ddATP, ddCTP, ddGTP and ddTTPs.
The manganese and metal ion buffer will conveniently, although not necessarily, be stored separately and only mixed when it is desired to carry out the sequencing reaction. Thus, the kit for DNA sequencing will preferably contain, as a first component, a metal ion buffer together with a buffering agent for regulating the pH to between pH 6 and pH 9, preferably about pH 8, deoxynucleotides and dye-labeled ddNTPs, and, as a second component, manganese ion together with a buffering agent for regulating the pH to between pH 3 to pH 7, preferably about pH 6, for example 2-(N-morpholino)ethanesulfonic acid. A DNA polymerase may also be included in the kit, preferably a DNA Pol I polymerase and most preferably a thermostable DNA polymerase, that contains a tyrosine in the dideoxy binding domain at a position analogous to that occupied by phenylalanine in unmutated polymerase. The kit may also contain a pyrophosphatase, for example, an inorganic pyrophosphatase such as that from Thermoplasma acidophilwn. The polymerase and pyrophosphatase will conveniently be included in the first component of the kit. The kit may also contain sources of other metal ions, for example magnesium and conveniently salts of such metal ions. These additional optional metal ions will conveniently be in the second component of the kit.
The concentration of the manganese ions and metal ion buffer will be such that they can be mixed directly to give the concentrations required for the sequencing reaction or they can be diluted readily to give the required concentrations. While the second component containing the manganese ions is buffered to about pH 6, the mixture resulting from adding the two components together will have a pH of about 8, e.g. pH 7 to pH 9.
In a further aspect, the present invention provides a method for sequencing DNA which comprises performing a DNA sequencing reaction in the presence of dye-labeled ddNTPs and manganese, at a concentration of between 0.5mM and 3mM, and preferably also in the 6 presence of a metal ion buffer, for example tartaric acid, at a concentration of between 5mM and 50mM, in the reaction mixture.
In a further aspect, the present invention provides a solution containing a metal ion buffer together with a buffering agent for regulating the pH to about pH 8, deoxynucleotides, and dye-labeled ddNTPs. Preferably the solution also contains a thermostable Pol I family DNA polymerase, more preferably a polymerase which has a tyrosine substituted for a phenylalanine in the nucleotide binding site.
Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.
Brief Description of the Figures
Figure 1 shows DNA sequencing results from an automated fluorescent DNA sequencing apparatus (ABI model 373 instrument) for an exemplary sequencing in which the polymerization step was carried out in the presence of manganese and a metal ion buffer.
Figure 2 shows DNA sequencing results corresponding to the results shown in Fig. 1, except that manganese was not included in the reaction mix.
Figure 3 shows the structure of the four dye labeled dideoxynucleotides utilized in the examples below. Each of the structures is identified with a Roman numeral, which is referenced in the solution preparation in Example 1.
Description of the Preferred Embodiments
The following examples serve to illustrate formulations of the present invention and their use in a sequencing reaction. These examples are in no way intended to limit the scope of the invention.
Example 1 - Solution Preparation
In the following "pre-mix" protocol all the reagents are contained in two solutions; reagent mix A and reagent mix B. 7 Reagent Mix A
The following reagents were combined to make 10ml of reagent mix A. (Roman numerals next to each of the ddNTPs designate the attached label as shown in Figure 3.):
2.5 ml 1 M HEPPS N-(2-hydroxyethyl) piperazine-N'-(3-propanesulfonic acid) pH 8.0
500 μl 1 M tartaric acid pH 8.0
50,000 units Thermo Sequenase DNA polymerase
2 units Thermoplasma acidophilum inorganic pyrophosphatase lOOμllOOmMdATP lOOμllOOmMdTTP lOOμllOOmMdCTP
500μll00mMdITP
9.375 μl 100 μM dye-labeled ddATP (I)
90 μl 100 μM dye-labeled ddCTP (II) 6.75 μl 100 μM dye-labeled ddGTP (III)
165 μl 100 μM dye-labeled ddTTP (IV)
10μl50mMEDTA
1 ml glycerol
The volume was made up to 10 ml with deionized H2O.
Reagent Mix B
The following reagents were combined to make 10 ml of reagent mix B:
10 μl 1M MES 2-(N-morpholino)ethanesulfonic acid. pH 6.0 200 μl 1M MgCl2 75 μl 1M MnSO4
The volume was made up to 10 ml with deionized H2O. 8 Example 2 - DNA Sequencing
4 μl reagent mix A, 4 μl reagent mix B, 200 ng M13mp 18 DNA, 5 pmole of primer (M13 - 40 Forward 5'-GTTTTCCCAGTCACGAC), and deionized water to a total volume of 20 μl were mixed together and subjected to 25 cycles of 96°C 30 seconds, 50°C 15 seconds, and 60°C 4 minutes in a thermal cycler. After cycling, 4μl of a solution which contained 1.5 M sodium acetate, 250 mM EDTA was added. The solution was mixed and 4 volumes (lOOμl) of ethanol added. The DNA was precipitated by incubation on ice for 15-20 minutes followed by centrifugation. The supernatant was removed and the pellet was washed with 70% ethanol, dried and resuspended in 4μl of formamide containing loading dye. The resuspended DNA was then run on an automated fluorescent DNA sequencing apparatus (ABI model 373 instrument). The result from the machine of the DNA sequence is shown as Figure 1. The corresponding result when the manganese was not included in the reaction mix is shown in Figure 2.
All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the invention pertains. All references cited in this disclosure are incorporated by reference to the same extent as if each reference had been incorporated by reference in its entirety individually.
One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The solutions, kits, methods, and specific compounds described herein as presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention are defined by the scope of the claims.
It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. For example, those skilled in the art will recognize that the invention may be 9 practiced using a variety of different metal ion buffers, pH buffers, dye labels, and/or concentrations of manganese, as well as additional reaction or kit components.
The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, in each instance herein any of the terms "comprising", "consisting essentially of and "consisting of may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.
In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.
Thus, additional embodiments are within the scope of the invention and within the following claims.

Claims

10 Claims What is claimed is:
1. A solution comprising manganese ion at a concentration of between 0.5mM to 3mM, a metal ion buffer at a concentration of 5mM to 50mM, and substituent-labeled dideoxynucleotides .
2. The solution of claim 1, wherein said substituent-labeled dideoxynucleotides are dye- labeled dideoxynucleotides.
The solution of claim 2, buffered to a pH between 6 and 8.5.
4. The solution of claim 2, wherein said manganese ion is at a concentration of between 0.5mM and 2.0mM.
5. The solution of claim 2, further comprising a thermostable DNA Pol I polymerase.
6. The solution of claim 5, wherein said thermostable DNA Pol I polymerase has a tyrosine replacing a phenylalanine in the nucleotide binding domain.
7. A method for sequencing DNA comprising the step of: performing a DNA sequencing reaction in the presence of substituent-labeled dideoxynucleotides, manganese at a concentration of between 0.5mM and 3mM, and a metal ion buffer at a concentration of between 5mM and 50mM.
8. The method of claim 7, wherein said substituent-labeled dideoxynucleotides are dye- labeled dideoxynucleotides.
9. The method of claim 8, wherein said DNA sequencing reaction is performed in the additional presence of a pyrophosphatase. 11
10. The method of claim 8, wherein said sequencing reaction is performed in the presence of a thermostable DNA Pol I polymerase.
11. The method of claim 10, wherein said thermostable DNA Pol I polymerase has a tyrosine replacing a phenylalanine in the nucleotide binding domain.
12. A kit comprising a first component comprising a metal ion buffer together with a buffering agent for regulating the pH to about pH 8, and substituent-labeled dideoxynucleotides; and a second component comprising manganese ion together with a buffering agent for regulating the pH to about pH 6.
13. The kit of claim 12, wherein said substituent-labeled dideoxynucleotides are dye-labeled dideoxynucleotides.
14. The kit of claim 13, further comprising a thermostable DNA Pol I polymerase.
15. The kit of claim 14, wherein said thermostable DNA Pol I polymerase has a tyrosine replacing a phenylalanine in the nucleotide binding domain.
16. The kit of claim 13 , further comprising a pyrophosphatase.
17. A solution comprising a metal ion buffer together with a buffering agent for regulating the pH to about pH 8, a first plurality of deoxynucleotides and a second plurality of substituent-labeled dideoxynucleotides.
18. The solution of claim 17, wherein said substituent-labeled dideoxynucleotides are dye- labeled dideoxynucleotides.
19. The solution of claim 18, further comprising a thermostable Pol I family polymerase, wherein a tyrosine is substituted for a phenylalanine in the nucleotide binding site. 12
20. A method for sequencing DNA which comprises the step of: performing a DNA sequencing reaction in the presence of substituent-labeled dideoxynucleotides and manganese at a concentration of between 0.5mM and 3mM.
21. The method of claim 20, wherein said substituent-labeled dideoxynucleotides are dye- labeled dideoxynucleotides.
22. The method of claim 21, wherein said DNA sequencing reaction is performed in the additional presence of a pyrophosphatase.
23. The method of claim 21, wherein said sequencing reaction is performed in the presence of a thermostable DNA Pol I polymerase.
24. The method of claim 23, wherein said thermostable DNA Pol I polymerase has a tyrosine replacing a phenylalanine in the nucleotide binding domain.
PCT/US1999/001084 1998-01-23 1999-01-19 A method, reagent solution and kits for dna sequencing WO1999037810A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP99904129A EP1071812A4 (en) 1998-01-23 1999-01-19 A method, reagent solution and kits for dna sequencing
JP2000528716A JP2002510466A (en) 1998-01-23 1999-01-19 Methods, reagent solutions and kits for DNA sequencing

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1238598A 1998-01-23 1998-01-23
US09/012,385 1998-01-23

Publications (1)

Publication Number Publication Date
WO1999037810A1 true WO1999037810A1 (en) 1999-07-29

Family

ID=21754725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/001084 WO1999037810A1 (en) 1998-01-23 1999-01-19 A method, reagent solution and kits for dna sequencing

Country Status (3)

Country Link
EP (1) EP1071812A4 (en)
JP (1) JP2002510466A (en)
WO (1) WO1999037810A1 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019841A1 (en) * 1999-09-17 2001-03-22 Amersham Pharmacia Biotech, Inc. Charge-modified nucleic acid terminators
EP1086115A2 (en) * 1998-06-10 2001-03-28 Intergen Company Purines and pyrimidines linked to a quencher
US6811979B2 (en) * 2000-10-11 2004-11-02 Applera Corporation Fluorescent nucleobase conjugates having anionic linkers
US7169560B2 (en) 2003-11-12 2007-01-30 Helicos Biosciences Corporation Short cycle methods for sequencing polynucleotides
US7220549B2 (en) 2004-12-30 2007-05-22 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing
US7297518B2 (en) 2001-03-12 2007-11-20 California Institute Of Technology Methods and apparatus for analyzing polynucleotide sequences by asynchronous base extension
US7397546B2 (en) 2006-03-08 2008-07-08 Helicos Biosciences Corporation Systems and methods for reducing detected intensity non-uniformity in a laser beam
US7462449B2 (en) 1999-06-28 2008-12-09 California Institute Of Technology Methods and apparatuses for analyzing polynucleotide sequences
US7476734B2 (en) 2005-12-06 2009-01-13 Helicos Biosciences Corporation Nucleotide analogs
US7482120B2 (en) 2005-01-28 2009-01-27 Helicos Biosciences Corporation Methods and compositions for improving fidelity in a nucleic acid synthesis reaction
US7501245B2 (en) 1999-06-28 2009-03-10 Helicos Biosciences Corp. Methods and apparatuses for analyzing polynucleotide sequences
US7635562B2 (en) 2004-05-25 2009-12-22 Helicos Biosciences Corporation Methods and devices for nucleic acid sequence determination
US7645596B2 (en) 1998-05-01 2010-01-12 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US7666593B2 (en) 2005-08-26 2010-02-23 Helicos Biosciences Corporation Single molecule sequencing of captured nucleic acids
US7981604B2 (en) 2004-02-19 2011-07-19 California Institute Of Technology Methods and kits for analyzing polynucleotide sequences
US9096898B2 (en) 1998-05-01 2015-08-04 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0655506B1 (en) * 1994-10-17 1996-09-18 President And Fellows Of Harvard College DNA polymerases having modified nucleotide binding site for DNA sequencing
US5871929A (en) * 1996-07-23 1999-02-16 Barnes; Wayne M. Suppression of pyrophosphorolysis in DNA sequencing and in other applications involving DNA replication

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PARKER L T, ET AL.: "AMPLITAQ DNA POLYMERASE, FS DYE-TERMINATOR SEQUENCING: ANALYSIS OF PEAK HEIGHT PATTERNS", BIOTECHNIQUES, INFORMA HEALTHCARE, US, vol. 21, no. 04, 1 October 1996 (1996-10-01), US, pages 694 - 699, XP002917137, ISSN: 0736-6205 *
See also references of EP1071812A4 *
TABOR S, RICHARDSON C C: "EFFECT OF MANGANESE IONS ON THE INCORPORATION OF DIDEOXYNUCLEOTIDESBY BACTERIOPHAGE T7 DNA POLYMERASE AND ESCHERICHIA COLI DNA POLYMERASE I", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 86, 1 June 1989 (1989-06-01), US, pages 4076 - 4080, XP002917136, ISSN: 0027-8424, DOI: 10.1073/pnas.86.11.4076 *

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212393B2 (en) 1998-05-01 2015-12-15 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US10214774B2 (en) 1998-05-01 2019-02-26 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US10208341B2 (en) 1998-05-01 2019-02-19 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US9957561B2 (en) 1998-05-01 2018-05-01 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US9725764B2 (en) 1998-05-01 2017-08-08 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US9540689B2 (en) 1998-05-01 2017-01-10 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US9458500B2 (en) 1998-05-01 2016-10-04 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US7645596B2 (en) 1998-05-01 2010-01-12 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US9096898B2 (en) 1998-05-01 2015-08-04 Life Technologies Corporation Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
EP1086115A2 (en) * 1998-06-10 2001-03-28 Intergen Company Purines and pyrimidines linked to a quencher
US7462449B2 (en) 1999-06-28 2008-12-09 California Institute Of Technology Methods and apparatuses for analyzing polynucleotide sequences
US7501245B2 (en) 1999-06-28 2009-03-10 Helicos Biosciences Corp. Methods and apparatuses for analyzing polynucleotide sequences
WO2001019841A1 (en) * 1999-09-17 2001-03-22 Amersham Pharmacia Biotech, Inc. Charge-modified nucleic acid terminators
US6811979B2 (en) * 2000-10-11 2004-11-02 Applera Corporation Fluorescent nucleobase conjugates having anionic linkers
US7687236B2 (en) 2000-10-11 2010-03-30 Applied Biosystems, Llc Fluorescent nucleobase conjugates having anionic linkers
US7429651B2 (en) 2000-10-11 2008-09-30 Applera Corporation Fluorescent nucleobase conjugates having anionic linkers
US7297518B2 (en) 2001-03-12 2007-11-20 California Institute Of Technology Methods and apparatus for analyzing polynucleotide sequences by asynchronous base extension
US7491498B2 (en) 2003-11-12 2009-02-17 Helicos Biosciences Corporation Short cycle methods for sequencing polynucleotides
US9012144B2 (en) 2003-11-12 2015-04-21 Fluidigm Corporation Short cycle methods for sequencing polynucleotides
US7897345B2 (en) 2003-11-12 2011-03-01 Helicos Biosciences Corporation Short cycle methods for sequencing polynucleotides
US7169560B2 (en) 2003-11-12 2007-01-30 Helicos Biosciences Corporation Short cycle methods for sequencing polynucleotides
US9657344B2 (en) 2003-11-12 2017-05-23 Fluidigm Corporation Short cycle methods for sequencing polynucleotides
US7981604B2 (en) 2004-02-19 2011-07-19 California Institute Of Technology Methods and kits for analyzing polynucleotide sequences
US7635562B2 (en) 2004-05-25 2009-12-22 Helicos Biosciences Corporation Methods and devices for nucleic acid sequence determination
US7220549B2 (en) 2004-12-30 2007-05-22 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing
US7482120B2 (en) 2005-01-28 2009-01-27 Helicos Biosciences Corporation Methods and compositions for improving fidelity in a nucleic acid synthesis reaction
US7666593B2 (en) 2005-08-26 2010-02-23 Helicos Biosciences Corporation Single molecule sequencing of captured nucleic acids
US9868978B2 (en) 2005-08-26 2018-01-16 Fluidigm Corporation Single molecule sequencing of captured nucleic acids
US7476734B2 (en) 2005-12-06 2009-01-13 Helicos Biosciences Corporation Nucleotide analogs
US7397546B2 (en) 2006-03-08 2008-07-08 Helicos Biosciences Corporation Systems and methods for reducing detected intensity non-uniformity in a laser beam

Also Published As

Publication number Publication date
JP2002510466A (en) 2002-04-09
EP1071812A1 (en) 2001-01-31
EP1071812A4 (en) 2002-05-15

Similar Documents

Publication Publication Date Title
WO1999037810A1 (en) A method, reagent solution and kits for dna sequencing
JP5280879B2 (en) Substituted propargyl ethoxyamide nucleoside
US5798210A (en) Derivatives utilizable in nucleic acid sequencing
ES2329562T3 (en) PROCEDURE FOR ANALYZING THE SEQUENCE OF AN ACID USING 4,7-DICLORO-RODOMIN COLORS.
CA2530798C (en) Synthesis and compositions of 2'-terminator nucleotides
US6316230B1 (en) Polymerase extension at 3′ terminus of PNA-DNA chimera
US5863727A (en) Energy transfer dyes with enhanced fluorescence
JP4414086B2 (en) Methods and compounds for analyzing nucleic acids by mass spectrometry
JP4393700B2 (en) DNA amplification method and sequencing method
US6001566A (en) DNA polymerase having 3'-intrinsic editing activity
JP2000510341A (en) A method for direct sequencing during template amplification
JPH08509857A (en) DNA sequencing method by mass spectrometry
WO1998006732A1 (en) Propargylethoxyamino nucleotides
JP2000500183A (en) Unsymmetrical benzoxanthene dye
EP3061764A1 (en) 5-formylcytosine specific chemical labeling method and related applications
US20220213542A1 (en) Sequencing by synthesis with energy transfer dye pairs
EP0785941B1 (en) Porphyrin labeling of polynucleotides
JP2003502013A (en) Process for the preparation of morpholino-nucleotides and its use for the analysis and labeling of nucleic acid sequences
JPH10504974A (en) Methods and compositions for stabilizing labeled nucleoside triphosphates
EP0745688B1 (en) The use of DNA polymerase having 3'-intrinsic editing activity
Welch Base additions sequencing scheme (BASS) and studies toward new sequencing methodologies
McGall Nucleoside triphosphate analogs for nonradioactive labeling of nucleic acids
US20030165880A1 (en) Fluorescence-based genotyping
Khan et al. Dye terminator chemistry: effects of substrate structure on sequencing analysis
McGuire Synthesis and studies of modified nucleotides and oligonucleotides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999904129

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 528716

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1999904129

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999904129

Country of ref document: EP